Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.

doi:10.1007/s10549-016-3883-z

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.

Breast cancer research and treatment - 1 Jul 2016

Kotoula Vassiliki, Karavasilis Vasilios, Zagouri Flora, Kouvatseas George, Giannoulatou Eleni, Gogas Helen, Lakis Sotiris, Pentheroudakis George, Bobos Mattheos, Papadopoulou Kyriaki, Tsolaki Eleftheria, Pectasides Dimitrios, Lazaridis Georgios, Koutras Angelos, Aravantinos Gerasimos, Christodoulou Christos, Papakostas Pavlos, Markopoulos Christos, Zografos George, Papandreou Christos, Fountzilas George

Abstract excerpt

The purpose of this study is to investigate whether the outcome of breast cancer (BC) patients treated with adjuvant chemotherapy is affected by co-mutated TP53 and PIK3CA according to stromal tumor-infiltrating lymphocytes (TILs). Paraffin tumors of all clinical subtypes from 1661 patients with operable breast cancer who were treated within 4 adjuvant trials with anthracycline-taxanes chemotherapy were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anthracyclines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Chemotherapy, Adjuvant

Share to Class I Phosphatidylinositol 3-Kinases

Share to Disease-Free Survival

Share to Lymphocytes, Tumor-Infiltrating

Share to Survival Analysis

Share to Taxoids

Source

Open in PubMed

Identifiers

PMID: 27369359
DOI: 10.1007/s10549-016-3883-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.PMID 27369359Read ↗

TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.Semantic proximity Read ↗

Early triple negative breast cancers in a Singapore cohort exhibit high PIK3CA mutation rates associated with low PD-L1 expressionSemantic proximity Read ↗

Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer.Semantic proximity Read ↗

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.Semantic proximity Read ↗

Oncogenic PIK3CA mutations in lobular breast cancer progression.Semantic proximity Read ↗

Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer.Semantic proximity Read ↗

Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.Semantic proximity Read ↗

PIK 3 CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison studySemantic proximity Read ↗

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2- breast cancer.Semantic proximity Read ↗

Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis.Semantic proximity Read ↗

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.Semantic proximity Read ↗

Association between PIK3CA activating mutations and outcomes in early-stage invasive lobular breast carcinoma treated with adjuvant systemic therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.